Ontology highlight
ABSTRACT: Background
Tissue-agnostic drug development provides a paradigm shift in precision medicine and requires innovative trial designs. However, outcome selection for such trials can prove challenging. The objectives of this review were to: (i) Identify and map core outcome sets (COS), across 11 immune-mediated inflammatory diseases (IMIDs) in order to facilitate the selection of relevant outcomes across the conditions for innovative trials of tissue-agnostic drug therapies. (ii) Compare outcomes or endpoints recommended by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to identify and highlight similarities and differences.Methods
The Core Outcome Measures in Effectiveness Trials (COMET), International Consortium for Health Outcomes Measurement (I
SUBMITTER: Aiyegbusi OL
PROVIDER: S-EPMC8761289 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature